{"id":57929,"date":"2026-02-25T14:35:20","date_gmt":"2026-02-25T06:35:20","guid":{"rendered":"https:\/\/flcube.com\/?p=57929"},"modified":"2026-02-25T14:35:21","modified_gmt":"2026-02-25T06:35:21","slug":"junshi-biosciences-partners-with-antengene-on-cancer-combination-js207-pd-1-vegf-bispecific-plus-atg-037-cd73-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57929","title":{"rendered":"Junshi Biosciences Partners with Antengene on Cancer Combination \u2013 JS207 PD\u20111\/VEGF Bispecific Plus ATG\u2011037 CD73 Inhibitor"},"content":{"rendered":"\n

Shanghai Junshi Biosciences Co., Ltd (HKG:\u202f1877<\/a>, SHA:\u202f688180<\/a>)<\/strong> announced a strategic collaboration<\/strong> with Antengene Corporation Limited (HKG: 6996<\/a>)<\/strong> to jointly explore the synergistic potential<\/strong> of combining JS207<\/strong> (anti\u2011PD\u20111\/VEGF bispecific antibody) with ATG\u2011037<\/strong> (oral CD73 inhibitor) for cancer patients in Mainland China<\/strong>. The partnership targets enhanced and sustained therapeutic responses<\/strong> in solid tumors through complementary immuno\u2011oncology mechanisms.<\/p>\n\n\n\n

Partnership Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Partner 1<\/strong><\/td>Junshi Biosciences (HKG:\u202f1877, SHA:\u202f688180)<\/td><\/tr>
Partner 2<\/strong><\/td>Antengene Corporation Limited (6996.HK)<\/td><\/tr>
Collaboration Type<\/strong><\/td>Strategic clinical combination study<\/td><\/tr>
Territory<\/strong><\/td>Mainland China<\/td><\/tr>
Combination Assets<\/strong><\/td>JS207 + ATG\u2011037<\/td><\/tr>
Therapeutic Goal<\/strong><\/td>Enhance and sustain anti\u2011tumor responses in solid tumors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Asset Profiles<\/h2>\n\n\n\n

JS207 \u2013 Junshi Biosciences<\/h3>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Class<\/strong><\/td>Recombinant humanized bispecific antibody<\/td><\/tr>
Targets<\/strong><\/td>PD\u20111<\/strong> + VEGF<\/strong> (dual targeting)<\/td><\/tr>
Differentiation<\/strong><\/td>VEGFA enhances antigen\u2011binding, T\u2011cell activation, and PD\u20111 endocytosis<\/td><\/tr>
Clinical Status<\/strong><\/td>Preclinical and clinical studies demonstrate encouraging anti\u2011tumor activity + manageable safety<\/td><\/tr>
Mechanism<\/strong><\/td>Dual immune checkpoint inhibition + anti\u2011angiogenesis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

ATG\u2011037 \u2013 Antengene<\/h3>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Class<\/strong><\/td>Oral small\u2011molecule CD73 inhibitor<\/td><\/tr>
Target<\/strong><\/td>CD73<\/strong> (ecto\u20115\u2032\u2011nucleotidase) \u2013 adenosine\u2011generating enzyme in tumor microenvironment<\/td><\/tr>
Advantages vs. Antibodies<\/strong><\/td>Superior tissue penetration; bypasses “hook effect”; complete cellular\u2011level CD73 inhibition<\/td><\/tr>
Preclinical Data<\/strong><\/td>More effective inhibition of cell\u2011surface CD73 enzymatic activity vs. anti\u2011CD73 mAbs<\/td><\/tr>
Mechanism<\/strong><\/td>Blocks adenosine production \u2192 reduces immunosuppression \u2192 enhances T\u2011cell function<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Synergistic Rationale<\/h2>\n\n\n\n
Pathway<\/th>JS207 Contribution<\/th>ATG\u2011037 Contribution<\/th>Combined Effect<\/th><\/tr><\/thead>
Immune Activation<\/strong><\/td>PD\u20111 blockade + VEGF\u2011mediated T\u2011cell enhancement<\/td>CD73 inhibition \u2192 reduced adenosine \u2192 restored T\u2011cell function<\/td>Synergistic immune activation<\/strong><\/td><\/tr>
Tumor Microenvironment<\/strong><\/td>Anti\u2011angiogenesis normalizes vasculature<\/td>Deep tissue penetration inhibits CD73 in hypoxic tumor cores<\/td>Enhanced drug delivery + immune cell infiltration<\/strong><\/td><\/tr>
Sustained Response<\/strong><\/td>Dual checkpoint\/angiogenesis blockade<\/td>Overcomes adenosine\u2011mediated resistance<\/td>Durable anti\u2011tumor immunity<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n